Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634582 · ClinicalTrials.gov registry record · Phase 2
Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00634582: Clinical Trial Phase 2 study, sponsored by Wake Forest University Health Sciences.
NCT00634582 is a Phase 2 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00634582, a Phase 2 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Paricalcitol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. It may also stop the growth of tumor cells in bone. PURPOSE: This phase II trial is studying how well paricalcitol works in treating patients with advanced prostate cancer and bone metastases.
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE quality-of-life assessment
- OTHER immunoenzyme technique
- DRUG paricalcitol
- PROCEDURE dual x-ray absorptometry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-01 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Why NCT00634582 stopped before completion
NCT00634582 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00634582 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00634582 about?
NCT00634582 is a clinical study titled "Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases". RATIONALE: Paricalcitol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. It may also stop the growth of tumor cells in bone. PURPOSE: This phase II trial is studying how well paricalcitol works in treating patients with advanced prostate cancer and b...
What is the current status of trial NCT00634582?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2009-01. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00634582?
The interventions under investigation include: laboratory biomarker analysis (OTHER), quality-of-life assessment (PROCEDURE), immunoenzyme technique (OTHER), paricalcitol (DRUG), dual x-ray absorptometry (PROCEDURE).
Who is sponsoring clinical trial NCT00634582?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00634582's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia